



Hepatorenal Syndrome

AKI in cirrhosis is not automatically HRS · It is a diagnosis of exclusion with a two-day albumin test built in

ALBUMIN 1 g/kg
× 2 days, then judge

WHAT IT ACTUALLY IS *a functional kidney problem caused by the circulation, not by the kidney*

THE MECHANISM

Portal hypertension drives splanchnic arterial vasodilatation, so the effective arterial blood volume falls despite obvious total-body fluid overload. The renin-angiotensin, sympathetic and vasopressin systems switch on, producing intense renal vasoconstriction.

THE KIDNEYS ARE NORMAL

There is no structural damage — which is why the urine is bland, why kidneys from HRS donors work normally when transplanted, and why the syndrome reverses when the circulation is corrected or the liver is replaced. Treat the circulation, not the kidney.

THE TWO FORMS

HRS-AKI (formerly type 1) is a **rapid rise in creatinine over days**, usually with a precipitant, and carries a very poor prognosis untreated. **HRS-NAKI** (formerly type 2) is a **slower decline with diuretic-refractory ascites**.

THE DIAGNOSTIC CRITERIA *the fixed creatinine cutoff was removed so treatment can start earlier*

Criterion	Detail
Cirrhosis with ascites	The syndrome occurs in decompensated cirrhosis with ascites , and also in acute liver failure and alcohol-related hepatitis.
AKI is present	A creatinine rise of 0.3 mg/dL or more within 48 hours, or 50% or more from baseline within 7 days . The old requirement for a creatinine above 2.5 mg/dL was abandoned, because waiting for that number meant treating far too late. Do not wait for a threshold value before acting .
No response to the albumin challenge	Withdraw diuretics and give albumin 1 g/kg daily (up to 100 g) for 2 consecutive days . Persisting AKI after that is the defining feature — it simultaneously excludes simple hypovolemia and treats it. This step is frequently skipped or under-dosed.
No shock	Hypotension requiring vasopressors from sepsis or hemorrhage points to acute tubular necrosis , which behaves and is managed differently.
No nephrotoxins	No recent NSAIDs, aminoglycosides, or iodinated contrast . Review the chart carefully; a single NSAID course is a classic and preventable precipitant.
No structural kidney injury	Proteinuria below 500 mg/day, fewer than 50 red cells per high-power field, and a normal renal ultrasound . Significant proteinuria or an active sediment means glomerular disease — think hepatitis B or C associated nephropathy, or IgA nephropathy in alcohol-related cirrhosis.

EXCLUDE THE COMMONER CAUSES FIRST *most AKI in cirrhosis is not HRS*

Cause	Clue and action
Hypovolemia	The commonest cause overall . Over-diuresis, large-volume paracentesis without adequate albumin cover, vomiting, diarrhea, and lactulose-induced losses. Responds to stopping diuretics and giving volume — which is exactly what the albumin challenge tests.
Infection	Do a diagnostic ascitic tap on every cirrhotic patient with AKI , whatever the temperature. Spontaneous bacterial peritonitis precipitates HRS and is frequently afebrile and asymptomatic. Also look for urinary, chest and skin sources.
Gastrointestinal bleeding	Variceal or otherwise, causing hypovolemia and renal hypoperfusion. Look for melaena and a rising urea disproportionate to the creatinine.
Acute tubular necrosis	Follows prolonged hypotension, sepsis or nephrotoxins. Granular casts and a higher urinary sodium support it, though these are unreliable in cirrhosis. It does not respond to vasoconstrictors.
Obstruction	Ultrasound every patient . Cheap, fast, and occasionally the whole answer.

TREAT *vasoconstrictor plus albumin, and refer for transplant in parallel*

- Stop diuretics, beta-blockers if hypotensive, NSAIDs and any nephrotoxin**, and treat the precipitant — drain and treat infection, control bleeding. **Give albumin cover with large-volume paracentesis** and treat spontaneous bacterial peritonitis with **albumin as well as antibiotics**, which reduces both HRS and mortality.
- Terlipressin plus albumin is first-line**. The vasoconstrictor reverses splanchnic vasodilatation and restores renal perfusion. **Reversal of HRS is achieved in a substantial minority, though without a clear survival benefit**, so the aim is to buy renal recovery and a bridge to transplant.
- Select patients carefully for terlipressin. Respiratory failure is the key harm** — avoid in significant hypoxemia or advanced cardiopulmonary disease, and monitor oxygenation closely. Also watch for **ischemic complications** in peripheral, mesenteric and coronary beds, and for hyponatremia.
- Where terlipressin is unavailable or contraindicated, use norepinephrine** with albumin in a monitored setting, or **midodrine with octreotide and albumin** outside critical care, which is less effective but usable on a ward.
- Refer for liver transplantation early — it is the only definitive treatment**. Renal replacement therapy is a bridge for transplant candidates or where recovery is plausible, not a destination in a patient who is not a candidate. **TIPS** helps selected patients. **Have the ceiling-of-care conversation in parallel**, because untreated HRS-AKI in a non-transplant candidate has a very short prognosis.

PEARLS & PITFALLS

- Terlipressin dosing: 1 mg IV every 6 h with albumin**, escalating to **2 mg every 6 h if creatinine has not fallen by 25% by day 3**. Monitor oxygen saturation closely: respiratory failure is the dose-limiting toxicity, and hypoxemia at baseline is a reason not to start.
- Tap the ascites in every cirrhotic patient with AKI**. Spontaneous bacterial peritonitis is often silent and precipitates HRS.
- Give the full albumin challenge before diagnosing HRS** — 1 g/kg for 2 days with diuretics stopped. Under-dosing it mislabels simple hypovolemia.
- Do not wait for a threshold creatinine**. That cutoff was deliberately removed so treatment could start earlier.
- Check for NSAIDs**. A single course is a classic, entirely preventable precipitant.
- Cover large-volume paracentesis with albumin**, and give albumin alongside antibiotics in SBP — both prevent HRS.
- Watch oxygenation on terlipressin**. Respiratory failure is its most important harm and the reason for careful selection.

